Spot 14: A marker of aggressive breast cancer and a potential therapeutic target

Endocrinology

Volumn 147, Issue 9, 2006, Pages 4048-4055

  Kinlaw, William B ^a,d   Quinn, Jennifer L ^a   Wells, Wendy A ^a   Roser Jones, Christopher ^a,c   Moncur, Joel T ^a,b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NORRIS COTTON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; GESTAGEN; HORMONE; LIPOPROTEIN LIPASE; LONG CHAIN FATTY ACID; NUCLEAR PROTEIN; PROTEIN SPOT 14; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CELL PROLIFERATION; DISEASE SEVERITY; DNA MICROARRAY; FATTY ACID SYNTHESIS; GENE AMPLIFICATION; HUMAN; LIPID METABOLISM; LIPOGENESIS; LYMPH NODE; MAMMARY GLAND; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY;

ANIMALS; BREAST NEOPLASMS; DNA, COMPLEMENTARY; FEMALE; HUMANS; LIPIDS; MICE; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33747589441     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-0463     Document Type: Short Survey

References (58)

1. Dang C 1999 Oncogenic alterations of metabolism. Trends Biochem Sci 24:68-72
2. Seelig S, Liaw C, Towle H, Oppenheimer J 1981 Thyroid hormone attenuates and augments hepatic gene expression at a pretranslational level. Proc Natl Acad Sci USA 78:4733-4737
3. Cunningham B, Moncur J, Maloney M, Kinlaw W 1997 "Spot 14" protein-protein interactions: evidence for both homo- and heterodimer formation in vivo. Endocrinology 138:5184-5188
4. Kinlaw WB, Tron P, Friedmann AS 1992 Nuclear localization and hepatic zonation of rat "spot 14" protein: immunohistochemical investigation employing anti-fusion protein antibodies. Endocrinology 131:3120-3122
5. Moncur J, Park J, Mohandes TK, Memoli V, Kinlaw W 1998 The "spot 14" gene resides on the telomeric end of the 11q13 amplicon and is expressed in lipogenic breast cancers. Proc Natl Acad Sci USA 95:6989-6994
6. Wells W, Schwartz G, Morganelli P, Cole B, Chambers J, Kinlaw WB 2006 Expression of "Spot 14" (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker. Breast Cancer Res Treat 98:231-240
7. Kinlaw W, Church J, Harmon J, Mariash C 1995 Direct evidence for a role of the "spot 14" protein in the regulation of lipid synthesis. J Biol Chem 270:16615-16618
8. Brown SB, Maloney M, Kinlaw WB 1997 "Spot 14" protein functions at the pretranslational level in the regulation of hepatic metabolism by thyroid hormone and glucose. J Biol Chem 272:2163-2166
9. Kinlaw WB, Tron P, Witters LA 1993 Thyroid hormone and dietary carbohydrate induce different hepatic zonation of both "spot 14" and acetyl CoA-carboxylase: a novel mechanism of coregulation. Endocrinology 133:645-650
10. Agius L, Robinson A, Girard J, Williamson D 1979 Alterations in the rate of lipogenesis in vivo in maternal liver and adipose tissue on premature weaning of lactating rats. Biochem J 186:1005-1008
11. Ball R, Friis R, SchoBenenberger C, Doppler W, Groner B 1988 Prolactin regulation of β-casein gene expression and of a cytosolic 120-kd protein in a cloned mouse mammary epithelial cell line. EMBO J 7:2089-2095
12. Weiss L, Hoffman G, Schreiber R, Andres H, Fuchs E, Korber E, Kolb H 1986 Fatty-acid biosynthesis in man, a pathway of minor importance. J Biol Chem 367:905-912
13. Kuhajda F 2000 Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16:202-208
14. Kuhajda F, Piantadosi S, Pasternack G 1989 Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease. New Engl J Med 321:636-641
15. Furuya Y, Akimoto S, Yasuda K, Ito H 1997 Apoptosis of androgen-independent prostate cell line induced by inhibition of fatty acid synthesis. Anticancer Res 17:4589-4594
16. Rashid A, Pizer E, Moga M, Milgraum L, Zahurak M, Pasternack G, Kuhajda F, Hamilton S 1997 Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 150:201-208
17. Pizer E, Wood F, Heine H, Romanstev F, Pasternak G, Kuhajda F 1996 Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56:1189-1193
18. Pizer E, Wood F, Pasternack G, Kuhajda F 1996 Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Res 56:745-751
19. Pizer E, Jackisch C, Wood F, Pasternak G, Davidson N, Kuhajda F 1996 Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56:2745-2747
20. Alli P, Pinn M, Jaffee E, McFaden J, Kuhajda F 2005 Fatty acid synthesis inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 24:39-46
21. Kridel S, Axelrod F, Rozenkrantz N, Smith J 2004 Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res 64:2070-2075
22. Lookene A, Skottova N, Olivecrona G 1994 Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipostatin (Orlistat). Eur J Biochem 222:395-403
23. Pizer E, Thupari J, Han W, Pinn M, Chrest F, Frehywot G, Townsend C, Kuhajda F 2000 Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60:213-218
24. Moncur J, Park J, Maloney M, Mohandas TK, Kinlaw WB 1997 Assignment of the human "spot 14" gene to 11q13.5 by fluorescence in situ hybridization. Cytogenet Cell Genet 78:131-132
25. Dickson C, Fantl V, Gillett C, Brookes S, Bartek J, Smith R, Fisher C, Barnes D, Peters G 1995 Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett 90:43-50
26. Bartkova M, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J 1994 Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57:353-361
27. Wang T, Cardiff R, Zukerberg L, Lees E, Arnold A, Schmidt E 1994 Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671
28. Martel P, Bingham C, McGraw C, Baker C, Morganelli P, Meng M, Armstrong JM, Moncur J, Kinlaw WB 2005 S14 protein in breast cancer cells: direct evidence for regulation by SREBP-1c, superinduction with progestin, and implication in cell growth. Exp Cell Res 312:278-288
29. Gradishar W 2005 The future of breast cancer: the role of prognostic factors. Breast Cancer Res Treat 89:S17-S26
30. Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Elsen M, van de Rijn M, Jeffrey S, Thorsen T, Quist H, Matese J, Brown P, Botstein D, Lonning P, Borrenson-Dale A 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874
31. Oskouian B 2000 Overexpression of fatty acid synthase in SKBR3 breast cancer cell line is mediated via a transcriptional mechanism. Cancer Lett 149:43-51
32. Jensen D, Bessesen D, Etienne J, Eckel R, Neville M 1991 Distribution and source of lipoprotein lipase in mouse mammary gland. J Lipid Res 32:733-742
33. Hamosh M, Yeager M, Shecter Y, Hamosh P 1976 Lipoprotein lipase in rat lung. Effect of dexamethasone. Biochim Biophys Acta 431:519-525
34. Chlebowski R, Blackburn G, Elashoff R, Thomson C, Goodman M, Shapiro A, Giulano A, Karanja N, Hoy M, Nixon D, Investigators TW 2005 Dietary fat reduction in postmenopausal women with primary breast cancer: phase III women's Intervention Nutrition Study (WINS). Proc Am Soc Clin Oncol 23:3s
35. Prentice RL, Caan B, Chlebowski RT, Patterson R, Kuller LH, Ockene JK, Margolis KL, Limacher MC, Manson JE, Parker LM, Paskett E, Phillips L, Robbins J, Rossouw JE, Sarto GE, Shikany JM, Stefanick ML, Thomson CA, Van Horn L, Vitolins MZ, Wactawski-Wende J, Wallace RB, Wassertheil-Smoller S, Whitlock E, Yano K, Adams-Campbell L, Anderson GL, Assaf AR, Beresford SA, Black HR, Brunner RL, Brzyski RG, Ford L, Gass M, Hays J, Heber D, Heiss G, Hendrix SL, Hsia J, Hubbell FA, Jackson RD, Johnson KC, Kotchen JM, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Henderson MM2006 Low-fat dietary pattern and risk of invasive breast cancer. JAMA 295:629-642
36. Yang Y, Han W, Morin P, Chrest F, Pizer E 2002 Activation of fatty acid synthase during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res 279:80-90
37. Kumar-Sinha C, Ignatoski K, Lippman M, Ethier S, Chinnaiyan A 2003 Transcriptome analysis of Her2 reveals a molecular connection to fatty acid synthesis. Cancer Res 63:132-139
38. Menendez J, Vellon L, Mehmi I, Oza B, Ropero S, Colomer R, Lupu R 2004 Inhibition of fatty acid synthase (FAS) suppresses Her2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 101:10715-10720
39. Menendez J, Vellon L, Lupu R 2005 Antitumoral actions of the anti-obesity drug orlistat (Xenical) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erb B-2) oncogene. Ann Oncol 16:1253-1267
40. Chalbos D, Chambon M, Ailhaud G, Rochefort H 1987 Fatty acid synthase and its mRNA are induced by progestins in breast cancer cells. J Biol Chem 262:9923-9926
41. Heemers H, Vanderhoydonc F, Heyns W, Verhoeven G, Swinnen J 2000 Progestins and androgens increase expression of spot 14 in T47-D breast tumor cells. Biochem Biophys Res Commun 269:209-212
42. Foretz M, Pacot C, Dugail I, Lemarchand P, Guichard C, Liepvre X, Berthelier-Lubrano C, Spiegelman B, Kim J, Ferre P, Foufelle F 1999 Add1/SREBP-1c is required in the activation of hepatic lipogenic gene expression by glucose. Mol Cell Biol 19:3760-3768
43. Rawson R 2003 The SREBP pathway: insights from insigs to insects. Nat Rev Mol Cell Biol 4:631-640
44. Yang Y, Morin P, Han W, Chen T, Bornman D, Gabrielson E, Pizer E 2003 Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res 282:132-137
45. Heemers H, Maes B, Foufelle F, Heyns W, Verhoeven G, Swinnen J 2001 Androgens stimulate lipogenic gene expression by activation of sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding pathway. Mol Endocrinol 15:1817-1828
46. Swinnen J, Heemers H, Deboel L, Foufelle F, Heyns W, Verhoeven G 2000 Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene 19:5173-5181
47. Iizuka K, Bruick R, Liang G, Horton J, Uyeda K 2004 Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc Natl Acad Sci USA 19:7281-7286
48. Sanchez-Rodriguez J, Kanininda-Tshilumbu J, Santos A, Perz-Castillo A 2005 The spot 14 protein inhibits growth and induces differentiation and cell death of human MCF-7 breast cancer cells. Biochem J 390:57-65
49. Zhu Q, Anderson G, Mucha G, Parks E, Metkowski J, Mariash C 2005 The Spot 14 protein is required for de novo lipid synthesis in the lactating mammary gland. Endocrinology 146:3343-3350
50. Ros MML, Garcia-Ruiz J, Moreno F 1990 Integration of lipid metabolism in the mammary gland and adipose tissue by prolactin during lactation. Moll Cell Biochem 93:185-194
51. Zhu Q, Mariash A, Margosian M, Gopinath S, Fareed M, Anderson G, Mariash C 2001 Spot 14 gene deletion increases hepatic de novo lipogenesis. Endocrinology 142:4263-4370
52. Wagner K, Krempler A, Qi Y, Park K, Henry M, Triplett A, Riedlinger G, Rucker E, Hennighausen L 2003 Tsg101 is essential for cell growth, proliferation, and cell survival of embryonic and adult tissues. Mol Cell Biol 23:150-162
53. Holland E, ed. 2004 Mammary gland cancer. New York: John Wiley
54. Hopkins A, Groom C 2002 The druggable genome. Nat Rev Drug Discov 1:727-730
55. Tilley J, Chen L, Fry D, Emerson S, Powers G, Biondi D, Varnell T, Trilles R, Guthrie R, Mennona F, Kaplan G, LeMahieu R, Carson M, Han R, Liu C, Palermo R, Ju G 1997 Identification of a small molecule inhibitor of the IL-2/IL-2-α receptor interaction which binds to IL-2. Am Chem Soc 119:7589-7590
56. Oneyama C, Nakano H, Sharma S 2002 UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug. Oncogene 21:2037-2050
57. Weissman H, Cochran A, Cunningham B, Fairbrother W, Keenen C, Meng G, de Vos A 1998 Crystal structure of the complex between VEGF and a receptor-blocking peptide. Biochemistry 37:17765-17772
58. LaFave LT, Augustin LB, Mariash CN 2006 Minireview: S14: insights from knockout mice. Endocrinology 147:4044-4047